# AMG-RAG on PharmGKB — Full Query/Response Transcript

All 15 validation items (ids 0–14). For each: the **query** sent to the system, the **gold reference** (PharmGKB curated sentence), our system's **generated answer**, and the **reasoning** (chain-of-thought the system produced over its per-question knowledge graph before answering). Model: Qwen2.5-14B (self-hosted Ollama, offline KG, `pgx` style).

## Item 0 — ✅ correct  ·  BERTScore F1 = 0.511

**Query:** What is the known pharmacogenomic effect of the CYP3A4*1, CYP3A4*17 variant on nifedipine?

**Gold reference:** CYP3A4 *17 is associated with decreased metabolism of nifedipine as compared to CYP3A4 *1.

**System answer:** The CYP3A4*17 variant leads to decreased metabolism of nifedipine due to reduced expression and activity of the CYP3A4 enzyme, potentially increasing plasma concentrations and side effects.

**System reasoning (chain-of-thought):**

> The pharmacogenomic effect of the CYP3A4*1 and CYP3A4*17 variants on nifedipine can be understood through their influence on drug metabolism. The wild-type allele, CYP3A4*1, is typically involved in metabolizing drugs like nifedipine without significant alterations to its activity or expression levels. However, the variant CYP3A4*17 leads to reduced expression and activity of the CYP3A4 enzyme. This reduction can result in decreased metabolism of nifedipine, leading to higher plasma concentrations and potentially increased side effects or toxicity for individuals carrying this genetic variant. Therefore, patients with the CYP3A4*17 allele may require dose adjustments or alternative treatments when using nifedipine due to its altered pharmacokinetics.

*Graph: 3 entities, 6 relations.*

---

## Item 1 — ⚠️ hedged  ·  BERTScore F1 = 0.222

**Query:** What is the known pharmacogenomic effect of the rs2909451 (DPP4) variant on sitagliptin?

**Gold reference:** Genotype TT is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.

**System answer:** The rs2909451 variant in the DPP4 gene is associated with differential pharmacogenomic effects on sitagliptin, potentially influencing drug response and efficacy by altering DPP4 function or expression.

**System reasoning (chain-of-thought):**

> The rs2909451 variant is a genetic marker that influences the pharmacogenomic effect of sitagliptin. The DPP4 gene, which encodes dipeptidyl peptidase-4 (DPP4) enzyme, plays a crucial role in the metabolism and efficacy of sitagliptin by degrading GLP-1, an incretin hormone that enhances glucose-dependent insulin secretion. Sitagliptin works by inhibiting DPP4 activity to increase GLP-1 levels, thereby improving glycemic control in patients with type 2 diabetes mellitus.
> 
> The rs2909451 variant is associated with the DPP4 gene (confidence: 0.80), indicating that this genetic variation may affect how DPP4 functions or its expression level. This association suggests a potential risk factor for variations in DPP4 activity due to the presence of this SNP.
> 
> Furthermore, there is evidence suggesting that rs2909451 has a pharmacogenomic effect on sitagliptin (confidence: 0.80). The reasoning path indicates that rs2909451 influences DPP4 function and metabolism of sitagliptin (confidence: 0.64), implying that individuals carrying this genetic variant may exhibit differential responses to sitagliptin treatment due to altered DPP4 activity or expression levels.
> 
> In summary, the rs2909451 variant likely impacts the pharmacogenomic response to sitagliptin by affecting DPP4 function and metabolism. This suggests that patients with this genetic variation may have different therapeutic outcomes when treated with sitagliptin compared to those without the variant.

*Graph: 3 entities, 6 relations.*

---

## Item 2 — ⚠️ hedged  ·  BERTScore F1 = 0.091

**Query:** What is the known pharmacogenomic effect of the rs706795 (FAIM2) variant on citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline?

**Gold reference:** Allele T is associated with increased response to citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to allele C.

**System answer:** The rs706795 variant in the FAIM2 gene is associated with altered response to citalopram and escitalopram, suggesting potential variability in efficacy or side-effect risk for these selective serotonin reuptake inhibitors (SSRIs).

**System reasoning (chain-of-thought):**

> The rs706795 variant located within the FAIM2 gene is suggested to have a pharmacogenomic effect on certain selective serotonin reuptake inhibitors (SSRIs) such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. Based on the provided medical knowledge graph information, there are direct connections indicating that rs706795 is a risk factor for FAIM2 and also directly linked to being a risk factor for citalopram and escitalopram with confidence levels of 0.80 each. Additionally, reasoning paths show an indirect link from rs706795 through FAIM2 to citalopram (confidence: 0.64). This suggests that the genetic variant in question may influence how individuals respond to these SSRIs, particularly citalopram and escitalopram. However, the graph does not provide specific details on the exact nature of this effect for all listed SSRIs or a comprehensive analysis across all six drugs mentioned. The information available indicates variability in clinical outcomes due to genetic differences at rs706795, but further research would be necessary to understand the full extent and mechanism of these effects for each SSRI.

*Graph: 8 entities, 56 relations.*

---

## Item 3 — ❌ wrong (fabricated; gold=null)  ·  BERTScore F1 = 0.126

**Query:** What is the known pharmacogenomic effect of the rs16918842 (OPRK1) variant on heroin?

**Gold reference:** Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele C.

**System answer:** The rs16918842 variant in the OPRK1 gene is associated with an increased risk of heroin use and adverse outcomes due to its influence on opioid receptor kappa 1 function or expression, potentially altering addiction susceptibility and drug response.

**System reasoning (chain-of-thought):**

> The rs16918842 variant is located within the OPRK1 gene, which encodes for the opioid receptor kappa 1. This genetic variation is considered a risk factor for heroin use and its associated outcomes due to its influence on how individuals respond to opioids like heroin. The pharmacogenomic effect of rs16918842 can be understood through the following steps:
> 
> 1. **Genetic Influence**: The OPRK1 gene plays a critical role in pain modulation and addiction pathways, making it an important target for studying genetic influences on opioid use disorders.
> 2. **Variant Impact**: The rs16918842 variant within OPRK1 is associated with altered function or expression of the kappa opioid receptor, which can influence how individuals experience pain relief and reward from opioids such as heroin.
> 3. **Heroin Response**: Individuals carrying this genetic variant may exhibit differential responses to heroin in terms of addiction susceptibility, withdrawal symptoms, and overall drug effects due to changes in receptor activity or density.
> 4. **Risk Factor Relationship**: The rs16918842 variant is considered a risk factor for heroin use because it potentially modifies the neurobiological pathways involved in opioid dependence and addiction.

*Graph: 3 entities, 6 relations.*

---

## Item 4 — ✅ correct  ·  BERTScore F1 = 0.420

**Query:** What is the known pharmacogenomic effect of the CYP2C9*1, CYP2C9*3 variant on warfarin?

**Gold reference:** CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.

**System answer:** The CYP2C9*3 variant leads to decreased warfarin metabolism compared to the wild-type allele (CYP2C9*1), increasing the risk of bleeding complications and necessitating lower doses or more frequent monitoring.

**System reasoning (chain-of-thought):**

> The pharmacogenomic effect of CYP2C9*1 and CYP2C9*3 variants on warfarin can be understood through the following steps:
> 
> 1. **Understanding Genetic Variants**: 
>    - **CYP2C9*1** is the wild-type allele, meaning it represents the normal genetic sequence of the CYP2C9 gene and typically results in normal enzyme activity.
>    - **CYP2C9*3** is a variant that leads to reduced enzyme activity compared to the wild-type allele (CYP2C9*1).
> 
> 2. **Role of CYP2C9 Enzyme**: 
>    - The CYP2C9 enzyme plays a crucial role in metabolizing warfarin, an anticoagulant medication used to prevent blood clots.
> 
> 3. **Pharmacogenomic Impact**:
>    - Individuals with the CYP2C9*1 variant (normal allele) will have normal metabolism of warfarin, leading to typical therapeutic effects and dosing requirements.
>    - Individuals carrying the CYP2C9*3 variant exhibit reduced enzyme activity, which means they metabolize warfarin more slowly. This can lead to higher levels of warfarin in their system, potentially increasing the risk of bleeding complications due to over-anticoagulation.
> 
> 4. **Clinical Implications**:
>    - Patients with CYP2C9*3 variant require careful monitoring and possibly lower doses of warfarin compared to those without this variant (i.e., having only CYP2C9*1).
>    - The presence of the CYP2C9*3 variant is a risk factor for adverse effects related to warfarin therapy, necessitating personalized dosing based on genetic testing results.
> 
> 5. **Interactions Between Variants**:
>    - There is an interaction between CYP2C9*1 and CYP2C9*3 variants in the context of warfarin pharmacogenomics, indicating that patients with both alleles (heterozygous for *1/*3) will have intermediate enzyme activity levels.
> 
> In summary, the presence of the CYP2C9*3 variant significantly impacts how individuals metabolize warfarin, leading to potential dose adjustments and increased monitoring requirements compared to those without this genetic variation.

*Graph: 3 entities, 8 relations.*

---

## Item 5 — ⚠️ hedged  ·  BERTScore F1 = 0.299

**Query:** What is the known pharmacogenomic effect of the rs2285676 (KCNJ11) variant on sitagliptin?

**Gold reference:** Genotype GG is associated with increased response to sitagliptin in people with Diabetes Mellitus, Type 2.

**System answer:** The rs2285676 variant in the KCNJ11 gene is associated with altered sitagliptin efficacy or side effects in individuals carrying this genetic variation.

**System reasoning (chain-of-thought):**

> The rs2285676 variant located within the KCNJ11 gene is associated with a pharmacogenomic effect on sitagliptin. The KCNJ11 gene encodes for a potassium channel protein that plays a role in insulin secretion and diabetes treatment, making it relevant to drugs like sitagliptin which are used in managing type 2 diabetes. Sitagliptin works by increasing levels of incretin hormones, thereby stimulating insulin release. However, the presence of the rs2285676 variant within KCNJ11 modifies how sitagliptin affects individuals carrying this genetic variation. The confidence level for the association between rs2285676 and its effect on sitagliptin is 0.80, indicating a strong likelihood that this genetic variant influences drug response to sitagliptin. This suggests that patients with the rs2285676 variant may experience altered efficacy or side effects when taking sitagliptin compared to those without the variant.

*Graph: 3 entities, 8 relations.*

---

## Item 6 — ✅ correct  ·  BERTScore F1 = 0.506

**Query:** What is the known pharmacogenomic effect of the CYP2C9*11 variant on warfarin?

**Gold reference:** CYP2C9 *11/*11 is associated with decreased dose of warfarin.

**System answer:** The CYP2C9*11 variant is associated with decreased warfarin metabolism, leading to a higher risk of bleeding complications and the need for lower warfarin doses.

**System reasoning (chain-of-thought):**

> The CYP2C9*11 variant is a genetic polymorphism that affects the metabolism of warfarin. Warfarin, an anticoagulant medication used to prevent blood clots, has its efficacy and safety significantly influenced by genetic variations such as the CYP2C9*11 variant. The pharmacogenomic effect of this variant on warfarin is primarily related to reduced metabolic activity due to decreased enzyme function caused by the genetic variation. This leads to a slower metabolism of warfarin in individuals carrying the CYP2C9*11 allele, potentially resulting in higher plasma levels and increased risk for adverse effects such as bleeding complications. Therefore, patients with this variant may require lower doses of warfarin compared to those without the variant to achieve therapeutic anticoagulation while minimizing risks.

*Graph: 2 entities, 2 relations.*

---

## Item 7 — ⚠️ hedged  ·  BERTScore F1 = 0.233

**Query:** What is the known pharmacogenomic effect of the rs163184 (KCNQ1) variant on sitagliptin?

**Gold reference:** Genotype GG is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.

**System answer:** The rs163184 variant in the KCNQ1 gene is associated with a pharmacogenomic effect on sitagliptin, potentially altering its efficacy or response due to its influence on insulin secretion and glucose homeostasis.

**System reasoning (chain-of-thought):**

> The rs163184 variant is located within the KCNQ1 gene, which encodes a potassium channel protein involved in insulin secretion and heart function. The pharmacogenomic effect of this variant on sitagliptin can be inferred from the connections provided in the medical knowledge graph. According to the reasoning paths outlined, rs163184 is associated with a risk factor for sitagliptin's pharmacogenomic effects (confidence: 0.70). This suggests that individuals carrying the rs163184 variant may experience altered efficacy or response to sitagliptin due to its influence on KCNQ1 function, which in turn affects insulin secretion and potentially glucose homeostasis. However, without specific external studies or data, we cannot provide detailed information about the exact nature of this effect (e.g., whether it increases or decreases efficacy). The confidence levels indicate a moderate level of certainty regarding the association between rs163184 and sitagliptin's pharmacogenomic effects.

*Graph: 4 entities, 12 relations.*

---

## Item 8 — ✅ correct  ·  BERTScore F1 = 0.430

**Query:** What is the known pharmacogenomic effect of the CYP2B6*1, CYP2B6*18 variant on efavirenz?

**Gold reference:** CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.

**System answer:** The CYP2B6*18 variant is associated with reduced metabolism of efavirenz compared to the common CYP2B6*1 allele, potentially leading to increased plasma concentrations and higher risk of side effects.

**System reasoning (chain-of-thought):**

> The pharmacogenomic effect of the CYP2B6*1 and CYP2B6*18 variants on efavirenz can be understood through their influence on drug metabolism. The CYP2B6 gene encodes an enzyme that plays a crucial role in metabolizing efavirenz, which is an antiretroviral medication used to treat HIV infection. 
> 
> CYP2B6*1 is described as a common allele of the CYP2B6 gene and influences the metabolism of efavirenz. This suggests that individuals with this variant may have normal or near-normal enzyme activity, leading to typical metabolic rates for efavirenz.
> 
> On the other hand, CYP2B6*18 is associated with reduced enzyme activity compared to the wild-type allele (CYP2B6*1). Therefore, patients carrying the CYP2B6*18 variant are likely to experience altered pharmacokinetics of efavirenz due to decreased metabolic capacity. This could result in higher plasma concentrations and potentially increased side effects or toxicity.
> 
> The reasoning paths indicate a relationship between these genetic variants where CYP2B6*1 is considered a risk factor for the presence of CYP2B6*18, suggesting that individuals with CYP2B6*1 may have a predisposition to also carry CYP2B6*18. However, this connection has moderate confidence (0.70), indicating it should be interpreted cautiously.
> 
> In summary, the pharmacogenomic effect of these variants on efavirenz metabolism implies that patients with CYP2B6*18 may require dose adjustments or monitoring due to potential altered drug levels compared to those with the more common CYP2B6*1 variant.

*Graph: 3 entities, 6 relations.*

---

## Item 9 — ✅ correct  ·  BERTScore F1 = 0.370

**Query:** What is the known pharmacogenomic effect of the CYP2C19*1, CYP2C19*2 variant on clomipramine, desmethyl clomipramine?

**Gold reference:** CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.

**System answer:** Individuals with the CYP2C19*2 variant have reduced metabolism of clomipramine and its metabolite desmethyl clomipramine compared to those with the wild-type allele (CYP2C19*1), potentially leading to higher plasma levels of clomipramine.

**System reasoning (chain-of-thought):**

> The pharmacogenomic effect of CYP2C19*1 and CYP2C19*2 variants on clomipramine and its metabolite desmethyl clomipramine can be understood through the following reasoning steps:
> 
> 1. **Wild-Type Allele (CYP2C19*1):** The CYP2C19*1 variant is considered a wild-type allele, meaning it does not typically alter the metabolism of drugs like clomipramine. It influences the metabolism of clomipramine but without any significant reduction in metabolic activity.
> 
> 2. **Variant Allele (CYP2C19*2):** The CYP2C19*2 variant is associated with reduced activity of the CYP2C19 enzyme, which plays a crucial role in metabolizing clomipramine and its active metabolite desmethyl clomipramine. This reduction can lead to altered pharmacokinetics and potentially higher plasma levels of clomipramine.
> 
> 3. **Interaction Between Variants:** There is an indirect relationship between CYP2C19*1 and CYP2C19*2, where the presence of CYP2C19*2 can be a risk factor for reduced activity compared to CYP2C19*1. This means that individuals carrying the CYP2C19*2 variant may experience altered metabolism of clomipramine and its metabolite desmethyl clomipramine, potentially leading to increased side effects or decreased efficacy.
> 
> 4. **Metabolism Pathway:** Clomipramine is primarily metabolized by the CYP2C19 enzyme into desmethyl clomipramine. Individuals with the CYP2C19*2 variant may have reduced capacity for this conversion, leading to higher levels of unmetabolized clomipramine in their system.
> 
> In summary, individuals carrying the CYP2C19*2 variant are likely to experience altered metabolism of clomipramine and its metabolite desmethyl clomipramine due to reduced enzyme activity compared to those with the wild-type allele (CYP2C19*1). This can have implications for dosing and monitoring in clinical practice.

*Graph: 4 entities, 12 relations.*

---

## Item 10 — ⚠️ hedged  ·  BERTScore F1 = 0.274

**Query:** What is the known pharmacogenomic effect of the rs7754840 (CDKAL1) variant on sitagliptin?

**Gold reference:** Genotype CG is associated with increased response to sitagliptin in people with Diabetes Mellitus, Type 2.

**System answer:** The rs7754840 variant in the CDKAL1 gene is associated with altered glucose metabolism and insulin secretion, which may influence sitagliptin efficacy in individuals carrying this genetic variation.

**System reasoning (chain-of-thought):**

> The rs7754840 variant located within the CDKAL1 gene is known to have a pharmacogenomic effect on sitagliptin, an oral antidiabetic medication used for managing type 2 diabetes. The medical knowledge graph indicates that this genetic variant acts as a risk factor for both CDKAL1 and sitagliptin, suggesting a potential interaction between the two. Specifically, the rs7754840 variant influences glucose metabolism and insulin secretion through its association with the CDKAL1 gene. Sitagliptin's pharmacological effect is influenced by this genetic variation, as indicated by the direct connection that sitagliptin is 'affected_by' rs7754840 (confidence: 0.60). This implies that individuals carrying the rs7754840 variant may experience altered responses to sitagliptin treatment due to differences in glucose metabolism and insulin secretion regulated by CDKAL1. The confidence levels provided suggest a moderate certainty regarding these associations, indicating further research could refine our understanding of how this genetic variation impacts sitagliptin efficacy and safety.

*Graph: 4 entities, 12 relations.*

---

## Item 11 — ❌ wrong (fabricated; gold=null)  ·  BERTScore F1 = 0.176

**Query:** What is the known pharmacogenomic effect of the rs371194629 (HLA-G) variant on methotrexate?

**Gold reference:** Genotype del/del is not associated with increased response to methotrexate in people with Arthritis, Rheumatoid.

**System answer:** The rs371194629 variant in the HLA-G gene is associated with a potential increased risk of adverse outcomes related to methotrexate therapy due to its influence on immune regulation pathways. However, the exact nature and magnitude of this effect are not yet fully established.

**System reasoning (chain-of-thought):**

> The rs371194629 variant is located within the HLA-G gene, which plays a role in immune regulation. Based on the provided knowledge graph, there are connections indicating that this genetic variant may act as a risk factor for methotrexate-related outcomes (confidence: 0.80). The reasoning path suggests that rs371194629 influences HLA-G expression or function, which in turn affects how an individual responds to methotrexate treatment (confidence: 0.64). This implies a potential pharmacogenomic effect where the presence of this variant could influence the efficacy or toxicity profile of methotrexate therapy due to its impact on immune regulation pathways that are relevant for drug response. However, without specific clinical studies or data linking rs371194629 directly to altered methotrexate metabolism or pharmacodynamics, the exact nature and magnitude of this effect remain speculative.

*Graph: 3 entities, 6 relations.*

---

## Item 12 — ⚠️ hedged  ·  BERTScore F1 = 0.274

**Query:** What is the known pharmacogenomic effect of the rs4664443 (DPP4) variant on sitagliptin?

**Gold reference:** Genotype GG is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.

**System answer:** The rs4664443 variant in the DPP4 gene is associated with altered sitagliptin response due to potential changes in DPP4 enzyme function or expression levels.

**System reasoning (chain-of-thought):**

> The rs4664443 variant is located within the DPP4 gene, which encodes for dipeptidyl peptidase-4 (DPP4), an enzyme that plays a crucial role in glucose metabolism. Sitagliptin, a drug used to treat type 2 diabetes mellitus, works by inhibiting DPP4 activity. The pharmacogenomic effect of the rs4664443 variant on sitagliptin suggests that this genetic variation may influence how effectively sitagliptin interacts with and modulates DPP4 enzyme function. Given the direct connections and reasoning paths provided in the medical knowledge graph, it is inferred that individuals carrying the rs4664443 variant might exhibit altered responses to sitagliptin treatment due to changes in DPP4 expression or activity levels. However, without specific data on how this genetic variation affects enzyme function or drug efficacy, the exact nature of the pharmacogenomic effect remains speculative based solely on the graph information.

*Graph: 3 entities, 6 relations.*

---

## Item 13 — ❌ wrong (flipped direction)  ·  BERTScore F1 = 0.533

**Query:** What is the known pharmacogenomic effect of the CYP2D6*1xN variant on codeine?

**Gold reference:** CYP2D6 *1xN is associated with increased metabolism of codeine.

**System answer:** The CYP2D6*1xN variant is associated with reduced codeine metabolism, leading to decreased analgesic efficacy and increased risk of adverse effects due to unmetabolized codeine.

**System reasoning (chain-of-thought):**

> The CYP2D6*1xN variant is a genetic polymorphism that significantly influences the metabolism of codeine. Codeine itself requires metabolic conversion to morphine by the enzyme encoded by the CYP2D6 gene for its analgesic effects. Individuals with the CYP2D6*1xN genotype typically have reduced or absent activity in the CYP2D6 enzyme, leading to a decreased ability to metabolize codeine into morphine. This results in lower efficacy of pain relief from codeine use and can also increase the risk of adverse events due to unmetabolized codeine accumulating in the body. Therefore, the pharmacogenomic effect of the CYP2D6*1xN variant on codeine is a reduced therapeutic response and potential for increased side effects or toxicity.

*Graph: 3 entities, 6 relations.*

---

## Item 14 — ❌ wrong  ·  BERTScore F1 = 0.150

**Query:** What is the known pharmacogenomic effect of the rs1799853 (CYP2C9) variant on sitagliptin?

**Gold reference:** Genotype TT is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.

**System answer:** The rs1799853 variant in CYP2C9 has a low confidence association with sitagliptin, indicating minimal impact on its metabolism due to the primary involvement of other enzymes like CYP3A4/5.

**System reasoning (chain-of-thought):**

> The rs1799853 variant within the CYP2C9 gene is known to influence drug metabolism, particularly for drugs metabolized by this enzyme. However, sitagliptin's primary metabolic pathway involves enzymes other than CYP2C9 (primarily CYP3A4/5). The medical knowledge graph indicates a low confidence connection between rs1799853 and sitagliptin, suggesting that the impact of this variant on sitagliptin metabolism is not well-established or significant. Therefore, while there may be some theoretical risk factors associated with the CYP2C9 genetic variation for drugs metabolized by this enzyme, the specific effect of rs1799853 on sitagliptin appears to be minimal due to its primary metabolic pathway involving other enzymes.

*Graph: 3 entities, 6 relations.*

---
